Hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.
(see ). It is important that hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension is measured with an accurate measuring device PRECAUTIONS, Information for Patients The dosing cup is provided with the 4 fl. oz. (115 mL) packaged product. The dosing cup fills for a 2.5 mL and for a 5 mL dose. Instruct the patient to fill to the line for the dose that has been prescribed. Do not f...
www.fda.gov/medwatch
www.parpharm.comEach 5 mL of hydrocodone polistirex and chlorpheniramine polistirex extended release (ER) oral suspension contains hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate and chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate. Hydrocodone is a centrally-acting narcotic antitussive. Chlorpheniramine is an antihistamine. Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is for oral use only.
Hydrocodone Polistirex
Sulfonated styrene-divinylbenzene copolymer complex with 4,5α-epoxy-3-methoxy-17-methylmorphinan-6-one.
[IC] [/IC]
Chlorpheniramine Polistirex
Sulfonated styrene-divinylbenzene copolymer complex with 2-[p-chloro-α-[2-(dimethylamino)ethyl]-benzyl]pyridine.
[IC] [/IC]
Inactive Ingredients
Ascorbic acid, D&C Yellow No. 10, flavors, high fructose corn syrup, modified food starch, methylparaben, polysorbate 80, polyvinyl acetate, propylene glycol, propylparaben, purified water, sodium ascorbate, sodium metabisulfite, sodium polystyrene sulfonate, sucrose, triacetin, xanthan gum.
Hydrocodone is a semisynthetic narcotic antitussive and analgesic with multiple actions qualitatively similar to those of codeine. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act directly on the cough center. In excessive doses, hydrocodone, like other opium derivatives, will depress respiration. The effects of hydrocodone in therapeutic doses on the cardiovascular system are insignificant. Hydrocodone can produce miosis, euphoria, and physical and psychological dependence.
Chlorpheniramine is an antihistamine drug (H receptor antagonist) that also possesses anticholinergic and sedative activity. It prevents released histamine from dilating capillaries and causing edema of the respiratory mucosa. 1
Hydrocodone release from hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is controlled by an extended-release drug delivery system, which combines an ion-exchange polymer matrix with a diffusion rate-limiting permeable coating. Chlorpheniramine release is prolonged by use of an ion-exchange polymer system.
Following multiple dosing with hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension, hydrocodone mean (S.D.) peak plasma concentrations of 22.8 (5.9) ng/mL occurred at 3.4 hours. Chlorpheniramine mean (S.D.) peak plasma concentrations of 58.4 (14.7) ng/mL occurred at 6.3 hours following multiple dosing. Peak plasma levels obtained with an immediate-release syrup occurred at approximately 1.5 hours for hydrocodone and 2.8 hours for chlorpheniramine. The plasma half-lives of hydrocodone and chlorpheniramine have been reported to be approximately 4 and 16 hours, respectively.
Hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older.
Hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension is contraindicated in patients with a known allergy or sensitivity to hydrocodone or chlorpheniramine.
The use of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is contraindicated in children less than 6 years of age due to the risk of fatal respiratory depression.
Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.
As with all narcotics, hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension produces dose-related respiratory depression by directly acting on brain stem respiratory centers. Hydrocodone affects the center that controls respiratory rhythm and may produce irregular and periodic breathing. Caution should be exercised when hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is used postoperatively and in patients with pulmonary disease, or whenever ventilatory function is depressed. If respiratory depression occurs, it may be antagonized by the use of naloxone hydrochloride and other supportive measures when indicated (see ). OVERDOSAGE
The respiratory depressant effects of narcotics and their capacity to elevate cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or a pre-existing increase in intracranial pressure. Furthermore, narcotics produce adverse reactions, which may obscure the clinical course of patients with head injuries.
The administration of narcotics may obscure the diagnosis or clinical course of patients with acute abdominal conditions.
Chronic use of narcotics may result in obstructive bowel disease especially in patients with underlying intestinal motility disorder.
The use of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is contraindicated in children less than 6 years of age (see ). CONTRAINDICATIONS
In pediatric patients, as well as adults, the respiratory center is sensitive to the depressant action of narcotic cough suppressants in a dose-dependent manner. Caution should be exercised when administering hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension to pediatric patients 6 years of age and older. Overdose or concomitant administration of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension with other respiratory depressants may increase the risk of respiratory depression in pediatric patients. Benefit to risk ratio should be carefully considered, especially in pediatric patients with respiratory embarrassment (e.g., croup) (see ). PRECAUTIONS
Caution is advised when prescribing this drug to patients with narrow-angle glaucoma, asthma, or prostatic hypertrophy.
As with any narcotic agent, hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension should be used with caution in elderly or debilitated patients and those with severe impairment of hepatic or renal function, hypothyroidism, Addison's disease, prostatic hypertrophy, or urethral stricture. The usual precautions should be observed and the possibility of respiratory depression should be kept in mind.
Patients should be advised that hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension may produce marked drowsiness and impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.
Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension must not be diluted with fluids or mixed with other drugs as this may alter the resin-binding and change the absorption rate, possibly increasing the toxicity.
Patients should be advised to measure hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension with an accurate measuring device. A household teaspoon is not an accurate measuring device and could lead to overdosage. A pharmacist can recommend an appropriate measuring device and can provide instructions for measuring the correct dose.
The dosing cup is provided with the 4 fl. oz. (115 mL) packaged product. The dosing cup fills for a 2.5 mL and for a 5 mL dose. Instruct the patient to fill to the line for the dose that has been prescribed. Rinse the measuring device after each use.
Shake well before using.
Keep out of the reach of children.
Hydrocodone suppresses the cough reflex; as with all narcotics, caution should be exercised when hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is used postoperatively, and in patients with pulmonary disease.
Patients receiving narcotics, antihistaminics, antipsychotics, antianxiety agents, or other CNS depressants (including alcohol) concomitantly with hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension may exhibit an additive CNS depression. When combined therapy is contemplated, the dose of one or both agents should be reduced.
The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.
The concurrent use of other anticholinergics with hydrocodone may produce paralytic ileus.
Carcinogenicity, mutagenicity, and reproductive studies have not been conducted with hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension.
Hydrocodone has been shown to be teratogenic in hamsters when given in doses 700 times the human dose. There are no adequate and well-controlled studies in pregnant women. Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.
As with all narcotics, administration of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension to the mother shortly before delivery may result in some degree of respiratory depression in the newborn, especially if higher doses are used.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The use of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is contraindicated in children less than 6 years of age (see and ). CONTRAINDICATIONS ADVERSE REACTIONS, Respiratory, Thoracic and Mediastinal Disorders
Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension should be used with caution in pediatric patients 6 years of age and older (see ). WARNINGS, Pediatric Use
Clinical studies of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
Nausea and vomiting may occur; they are more frequent in ambulatory than in recumbent patients. Prolonged administration of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension may produce constipation.
Death
Sedation, drowsiness, mental clouding, lethargy, impairment of mental and physical performance, anxiety, fear, dysphoria, euphoria, dizziness, psychic dependence, mood changes.
Ureteral spasm, spasm of vesical sphincters, and urinary retention have been reported with opiates.
Dryness of the pharynx, occasional tightness of the chest, and respiratory depression (see ). CONTRAINDICATIONS
Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension may produce dose-related respiratory depression by acting directly on brain stem respiratory centers (see ). Use of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension in children less than 6 years of age has been associated with fatal respiratory depression. Overdose with hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension in children 6 years of age and older, in adolescents, and in adults has been associated with fatal respiratory depression. OVERDOSAGE
Rash, pruritus.
Hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension is a Schedule II narcotic. Psychic dependence, physical dependence and tolerance may develop upon repeated administration of narcotics; therefore, hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension should be prescribed and administered with caution. However, psychic dependence is unlikely to develop when hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is used for a short time for the treatment of cough. Physical dependence, the condition in which continued administration of the drug is required to prevent the appearance of a withdrawal syndrome, assumes clinically significant proportions only after several weeks of continued oral narcotic use, although some mild degree of physical dependence may develop after a few days of narcotic therapy.
Serious overdosage with hydrocodone is characterized by respiratory depression (a decrease in respiratory rate and/or tidal volume, Cheyne-Stokes respiration, cyanosis), extreme somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, and sometimes bradycardia and hypotension. Although miosis is characteristic of narcotic overdose, mydriasis may occur in terminal narcosis or severe hypoxia. In severe overdosage apnea, circulatory collapse, cardiac arrest and death may occur. The manifestations of chlorpheniramine overdosage may vary from central nervous system depression to stimulation.
Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote for respiratory depression which may result from overdosage or unusual sensitivity to narcotics including hydrocodone. Therefore, an appropriate dose of naloxone hydrochloride should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. Since the duration of action of hydrocodone in this formulation may exceed that of the antagonist, the patient should be kept under continued surveillance and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. For further information, see full prescribing information for naloxone hydrochloride. An antagonist should not be administered in the absence of clinically significant respiratory depression. Oxygen, intravenous fluids, vasopressors and other supportive measures should be employed as indicated. Gastric emptying may be useful in removing unabsorbed drug.
(see ). It is important that hydrocodone polistirex and chlorpheniramine polistirex extended-release oral suspension is measured with an accurate measuring device PRECAUTIONS, Information for Patients
The dosing cup is provided with the 4 fl. oz. (115 mL) packaged product. The dosing cup fills for a 2.5 mL and for a 5 mL dose. Instruct the patient to fill to the line for the dose that has been prescribed. Do not fill over the dose prescribed. Rinse with water after each use.
For prescriptions where a dosing device is not provided, a pharmacist can provide an appropriate measuring device and can provide instructions for measuring the correct dose. A household teaspoon is not an accurate measuring device and could lead to overdosage.
Each 5 mL of hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension contains hydrocodone polistirex equivalent to 10 mg hydrocodone bitartrate, and chlorpheniramine polistirex equivalent to 8 mg chlorpheniramine maleate. Shake well before using. Rinse the measuring device with water after each use.
Shake well before using.
5 mL every 12 hours; do not exceed 10 mL in 24 hours.
2.5 mL every 12 hours; do not exceed 5 mL in 24 hours.
This medicine is contraindicated in children under 6 years of age (see ). CONTRAINDICATIONS
NDC:17856-0235-1 in a CUP, UNIT-DOSE of 5 SUSPENSION, EXTENDED RELEASES
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension (CII)
(10 mg hydrocodone bitartrate and 8 mg chlorpheniramine maleate per 5 mL)
Read this Patient Information before you start taking Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.
What is Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension?
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is a prescription medicine used to treat cough and upper respiratory symptoms you can have with allergies or a cold. Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is for adults and children age 6 years and older.
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension contains two medicines, hydrocodone and chlorpheniramine. Hydrocodone is a narcotic cough suppressant. Chlorpheniramine is an antihistamine.
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension is a controlled substance (CII) because it contains hydrocodone that can be a target for people who abuse prescription medicines or street drugs. Keep your Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension in a safe place, to protect it from theft. Never give your Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension to anyone else, because it may cause death or harm them. Selling or giving away this medicine is against the law.
Who should not take Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension?
Do not take Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension if you:
What should I tell my doctor before taking Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension?
Before you take Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, tell your doctor if you:
Symptoms of withdrawal in a newborn baby may include:
If you take Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension regularly before your baby is born, your baby could have breathing problems.
Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.
How should I take Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension?
If you do not have a dosing cup for your medicine, ask your pharmacist to give you a measuring device to help you measure the correct amount of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. Do not use a household teaspoon to measure your medicine. You may accidently take too much.
[IC] [/IC]
If you take too much Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, call your doctor or go to the nearest hospital emergency room right away.
What should I avoid while taking Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension?
What are the possible side effects of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension?
Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension may cause serious side effects, including:
The most common side effects of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension are:
Tell your doctor if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
How should I store Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension?
General information about Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information Leaflet. Do not use Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension for a condition for which it was not prescribed. Do not give Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension to other people, even if they have the same condition. It may harm them and it is against the law.
This Patient Information Leaflet summarizes the most important information about Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension that is written for healthcare professionals.
For more information about Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension, contact Par Pharmaceutical Inc. at 1-800-828-9393 or www.parpharm.com.
What are the ingredients in Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended-Release Oral Suspension?
hydrocodone polistirex and chlorpheniramine polistirex Active Ingredient:
Ascorbic acid, D&C Yellow No. 10, flavors, high fructose corn syrup, modified food starch, methylparaben, polysorbate 80, polyvinyl acetate, propylene glycol, propylparaben, purified water, sodium ascorbate, sodium metabisulfite, sodium polystyrene sulfonate, sucrose, triacetin, xanthan gum. Inactive Ingredients:
This patient information has been approved by the U.S. Food and Drug Administration.
Distributed by:
Par Pharmaceutical Companies, Inc.
Spring Valley, NY 10977
I 09/14
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1087459 | HYDROcodone polistirex 10 MG / chlorpheniramine polistirex 8 MG in 5 mL 12HR Extended Release Oral Suspension | PSN | 2 |
| 1087459 | 12 HR chlorpheniramine polistirex 1.6 MG/ML / hydrocodone polistirex 2 MG/ML Extended Release Suspension | SCD | 2 |
| 1087459 | hydrocodone polistirex 10 MG / chlorpheniramine polistirex 8 MG per 5 ML 12HR Extended Release Oral Suspension | SY | 2 |
| Class | Version | Type | Effective |
|---|---|---|---|
| CHLORPHENIRAMINE Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| HYDROCODONE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17856-0235-1 | 2020-01-31 | C162847 | 48780-1 | 9d75b9d0-865c-f424-e053-dadaa90a57ce | Hydrocodone Polistirex and Chlorpheniramine Polistirex Extended Release Oral Suspension CII (10 mg hydrocodone bitartrate and 8 mg chlorpheniramine maleate per 5 mL) Rx only |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-0235-1 | Hydrocodone Polistirex and Chlorpheniramine Polisitrex | 5 mL in 1 CUP, UNIT-DOSE | SUSPENSION, EXTENDED RELEASE | 5 | 2 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-0235 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISITREX SUSPENSION, EXTENDED RELEASE [ATLANTIC BIOLOGICALS CORPS] | 2 | Legacy NDC, 1 package rows | 20150216_566d28f3-4b16-4881-9347-2175e5060ffb.zip |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 49884-235-33 | ML - Milliliter | 49884-235 | 25f1c9c8-a9b6-4184-9d5f-3fec80483a45 | 1 | 2012-07-24 |
| 49884-235-37 | ML - Milliliter | 49884-235 | 7a6feb71-995d-4cdc-98b5-dc27db994be2 | 1 | 2013-02-13 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CHLORPHENIRAMINE MALEATE | ACTIVE INGREDIENT | V1Q0O9OJ9Z | 2 | |
| HYDROCODONE BITARTRATE | ACTIVE INGREDIENT | NO70W886KK | 2 | |
| CHLORPHENIRAMINE | ACTIVE MOIETY | 3U6IO1965U | 2 | |
| HYDROCODONE | ACTIVE MOIETY | 6YKS4Y3WQ7 | 2 | |
| ASCORBIC ACID | INACTIVE INGREDIENT | PQ6CK8PD0R | 2 | |
| D&C YELLOW NO. 10 | INACTIVE INGREDIENT | 35SW5USQ3G | 2 | |
| HIGH FRUCTOSE CORN SYRUP | INACTIVE INGREDIENT | XY6UN3QB6S | 2 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 2 | |
| MODIFIED CORN STARCH (1-OCTENYL SUCCINIC ANHYDRIDE) | INACTIVE INGREDIENT | 461P5CJN6T | 2 | |
| POLYSORBATE 80 | INACTIVE INGREDIENT | 6OZP39ZG8H | 2 | |
| PROPYLENE GLYCOL | INACTIVE INGREDIENT | 6DC9Q167V3 | 2 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 2 | |
| SODIUM ASCORBATE | INACTIVE INGREDIENT | S033EH8359 | 2 | |
| SODIUM METABISULFITE | INACTIVE INGREDIENT | 4VON5FNS3C | 2 | |
| SODIUM POLYSTYRENE SULFONATE | INACTIVE INGREDIENT | 1699G8679Z | 2 | |
| SUCROSE | INACTIVE INGREDIENT | C151H8M554 | 2 | |
| TRIACETIN | INACTIVE INGREDIENT | XHX3C3X673 | 2 | |
| VINYL ACETATE | INACTIVE INGREDIENT | L9MK238N77 | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 | |
| XANTHAN GUM | INACTIVE INGREDIENT | TTV12P4NEE | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 17856-0235 | 17856-0235-1 |
| 49884-235 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ASCORBIC ACID | ASCORBIC ACID | PQ6CK8PD0R | SUPPOSITORY / RECTAL | 3 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 15 mg | ||
| TRIACETIN | TRIACETIN | XHX3C3X673 | SYSTEM / TRANSDERMAL | 22.1 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRALESIONAL | 0.1 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SPONGE / TOPICAL | 40 %w/w | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION, SOLUTION / INFILTRATION | 0.05 %w/v | ||
| SUCROSE | SUCROSE | C151H8M554 | INJECTABLE, LIPOSOMAL / INTRAVENOUS | 7560 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SUSPENSION / OPHTHALMIC | 0.6 %w/v | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / PERINEURAL | 0.05 %w/v | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | POWDER, FOR SUSPENSION / ORAL | 396 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / RECTAL | 0.02 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / TOPICAL | 5148 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, DELAYED RELEASE / ORAL | 1.7 mg | ||
| HIGH FRUCTOSE CORN SYRUP | HIGH FRUCTOSE CORN SYRUP | XY6UN3QB6S | SUSPENSION / ORAL | 20000 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | GRANULE, FOR SUSPENSION / ORAL | 80 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUPPOSITORY / VAGINAL | 28 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | SUSPENSION / AURICULAR (OTIC) | 1 %w/v | ||
| SODIUM ASCORBATE | SODIUM ASCORBATE | S033EH8359 | TABLET / ORAL | 30 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / TOPICAL | 0.8 %w/w | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET / ORAL | 233 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | OINTMENT / TOPICAL | 0.1 %w/w | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | GEL, METERED / TOPICAL | 1225 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SYSTEM / TOPICAL | 21 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION / SOFT TISSUE | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CAPSULE, EXTENDED RELEASE / ORAL | 2 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | LIQUID / ORAL | 29008 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 3.6 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IRRIGATION | 2 %w/v | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | SOLUTION / RECTAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | EMULSION / TOPICAL | 8 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION/ DROPS / OPHTHALMIC | 0.05 %w/v | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | TABLET, DELAYED RELEASE / ORAL | 1.9 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | DROPS / AURICULAR (OTIC) | 0.02 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | OINTMENT / RECTAL | 27 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION, EXTENDED RELEASE / ORAL | 4 mg | ||
| D&C YELLOW NO. 10 | D&C YELLOW NO. 10 | 35SW5USQ3G | PASTE / DENTAL | NA | ||
| SUCROSE | SUCROSE | C151H8M554 | LOZENGE / BUCCAL | NA | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | CAPSULE, COATED / ORAL | 25 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAVENOUS | 0.13 %w/v | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, POWDER, FOR SUSPENSION / INTRAMUSCULAR | 4 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | INJECTION / INTRA-ARTICULAR | 0.2 %w/v | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SOLUTION/ DROPS / AURICULAR (OTIC) | ADJ PH | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / PARENTERAL | 30 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / PERIDURAL | 1 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | JELLY / TOPICAL | 180 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | TABLET / SUBLINGUAL | 2 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / OPHTHALMIC | 0.01 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SOLUTION / INTRAVENOUS | 5 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, SOLUTION / INTRAVENOUS | 45 mg | ||
| SUCROSE | SUCROSE | C151H8M554 | POWDER, FOR SOLUTION / ORAL | 38666 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | INJECTION, SUSPENSION / INTRAVENOUS | 0.5 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, COATED / ORAL | 0.8 mg | ||
| SODIUM METABISULFITE | SODIUM METABISULFITE | 4VON5FNS3C | SUSPENSION/ DROPS / OPHTHALMIC | 0.1 %w/w | ||
| XANTHAN GUM | XANTHAN GUM | TTV12P4NEE | LOZENGE / ORAL | 1264 mg | ||
| POLYSORBATE 80 | POLYSORBATE 80 | 6OZP39ZG8H | TABLET, DELAYED RELEASE / ORAL | 4 mg | ||
| PROPYLENE GLYCOL | PROPYLENE GLYCOL | 6DC9Q167V3 | SYSTEM / TOPICAL | 4200 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SHAMPOO, SUSPENSION / TOPICAL | 0.15 %w/w |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-15 13:18:30 | 2026-09 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 4b0b4de00fa7… | |
| 2019-12-13 00:20 UTC | 2019-12 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 74a2ff9319b5… | |
| 2022-03-09 01:35 UTC | 2022-03 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 782e0a99824c… | |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 87673890dc5c… | |
| 2021-03-12 10:30 UTC | 2021-03 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 5aa47cf7b7d7… | |
| 2020-12-22 03:56 UTC | 2020-12 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 8869cabd3fbd… | |
| 2020-11-12 02:37 UTC | 2020-11 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | c0c555d07b60… | |
| 2019-12-14 00:12 UTC | 2019-12 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 3f01610625f2… | |
| 2019-09-15 20:21 UTC | 2019-09 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | b00525d2431f… | |
| 2019-07-19 19:46 UTC | 2019-07 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | ea99ee380514… | |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 6a51e52b5d6a… | |
| 2024-02-18 07:12 UTC | 2024-02 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 1c564ffb4f44… | |
| 2023-12-20 04:57 UTC | 2023-12 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | ea1830bbd6c7… | |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | a72a2bbeb626… | |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 9b2671bbb829… | |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | a67488948f0b… | |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 3f0d92c62455… | |
| 2023-05-13 08:27 UTC | 2023-05 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 053a50430f4f… | |
| 2023-01-26 05:58 UTC | 2023-01 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | RS | 2010-10-01 | 3bdfa0b2c4d7… | |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A091632-001 | HYDROCODONE POLISTIREX AND CHLORPHENIRAMINE POLISTIREX | EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML | SUSPENSION, EXTENDED RELEASE / ORAL | AB | 2010-10-01 | 3a93d1ddd44b… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A091632-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A091632-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A091632-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | A091632-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | A091632-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A091632-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | A091632-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | A091632-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | A091632-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | A091632-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | A091632-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | A091632-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | A091632-001 | AB | 1 | ea99ee380514… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | A091632-001 | AB | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | A091632-001 | AB | 1 | f41ea6bd6efb… |
| 2022-09-29 23:25 UTC | 2022-09 | A091632-001 | AB | 1 | e64feba35796… |
| 2022-07-09 03:26 UTC · 3 captures of this ZIP | 2022-07 | A091632-001 | AB | 1 | cb3db0bc1861… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| f75c6ba1-6695-4bcb-88ec-63efd2acdf92 | 566d28f3-4b16-4881-9347-2175e5060ffb | 2014-10-17 | Warnings, Adverse reactions | f75c6ba1-6695-4bcb-88ec-63efd2acdf92 566d28f3-4b16-4881-9347-2175e5060ffb |
Adverse event summaries are temporarily unavailable. Other product information remains available.